Tuesday, December 14, 2021
Genprex (GNPX)
Reqorsa Could Be The First Systemic Gene Therapy
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Genprex Has Developed a Proprietary System For Gene Delivery. The Oncoprex technology uses nanoparticles to deliver genes using intravenous administration rather than a viral vector delivered directly to the tumor site. The company’s first product, Reqorsa, uses the Oncoprex system to deliver a tumor suppressor gene. Reqorsa began a Phase 1/2 clinical trial in non-small cell lung cancer (NSCLC) and is expect to being a Phase 1/2 immunotherapy combination trial in early 2022.
Gene Therapy With A Tumor Suppressor Reqorsa was developed to deliver TUSC2 gene, a tumor suppressor gene. TUSC2 has been shown to stop pathways of cancer cell proliferation and start pathways that lead to cell death (apoptosis). These pathways may be additive or synergistic with actions of other drugs that act through intracellular signaling …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
